INTRODUCTION: Preoperative chemoradiotherapy (CRT) is the standard therapy for downstaging in locally advanced lower rectal cancer. However, it remains unclear whether rectal cancers downstaged by preoperative therapy show similar prognoses to those of the same stage without preoperative therapy. We previously demonstrated that preoperative CRT did not affect prognosis of rectal cancer with pathological T1N0 (pT1N0) stage in a single institute. Here, using a larger dataset, we compared prognoses of (y)pT1 rectal cancer stratified by the use of preoperative therapy and analyzed prognostic factors. METHODS: Cases of pT1N0 rectal cancer, registered between 2004 and 2016, were extracted from the Surveillance, Epidemiology, and End Results database. Patients were categorized as the "ypT1 group" if they had undergone preoperative therapy before surgery or as the "pT1 group" if they had undergone surgery alone. Overall survival (OS) and cancer-specific survival (CSS) between these groups of patients were compared. Factors associated with CSS and OS were identified by univariate and multivariate analyses. RESULTS: Among 3,757 eligible patients, ypT1 and pT1 groups comprised 720 and 3,037 patients, respectively. While ypT1 patients showed poorer CSS than ypT1 patients, there was no significant difference in OS. Preoperative therapy was not an independent prognostic factor for CSS or OS. Multivariate analysis identified age and histological type as significant factors associated with CSS. Sex, age, race, and number of lymph nodes dissected were identified as significant factors associated with OS. CONCLUSIONS: Prognosis among patients with (y)p T1N0 rectal cancer was similar irrespective of whether they underwent preoperative therapy, which is consistent with our previous observations.
INTRODUCTION: Preoperative chemoradiotherapy (CRT) is the standard therapy for downstaging in locally advanced lower rectal cancer. However, it remains unclear whether rectal cancers downstaged by preoperative therapy show similar prognoses to those of the same stage without preoperative therapy. We previously demonstrated that preoperative CRT did not affect prognosis of rectal cancer with pathological T1N0 (pT1N0) stage in a single institute. Here, using a larger dataset, we compared prognoses of (y)pT1 rectal cancer stratified by the use of preoperative therapy and analyzed prognostic factors. METHODS: Cases of pT1N0 rectal cancer, registered between 2004 and 2016, were extracted from the Surveillance, Epidemiology, and End Results database. Patients were categorized as the "ypT1 group" if they had undergone preoperative therapy before surgery or as the "pT1 group" if they had undergone surgery alone. Overall survival (OS) and cancer-specific survival (CSS) between these groups of patients were compared. Factors associated with CSS and OS were identified by univariate and multivariate analyses. RESULTS: Among 3,757 eligible patients, ypT1 and pT1 groups comprised 720 and 3,037 patients, respectively. While ypT1 patients showed poorer CSS than ypT1 patients, there was no significant difference in OS. Preoperative therapy was not an independent prognostic factor for CSS or OS. Multivariate analysis identified age and histological type as significant factors associated with CSS. Sex, age, race, and number of lymph nodes dissected were identified as significant factors associated with OS. CONCLUSIONS: Prognosis among patients with (y)p T1N0 rectal cancer was similar irrespective of whether they underwent preoperative therapy, which is consistent with our previous observations.
Authors: Niamh McCawley; Cillian Clancy; Brian D P O'Neill; Joseph Deasy; Deborah A McNamara; John P Burke Journal: Dis Colon Rectum Date: 2016-12 Impact factor: 4.585
Authors: Fabio Maria Vecchio; Vincenzo Valentini; Bruce D Minsky; Gilbert D A Padula; Ennapadam S Venkatraman; Mario Balducci; Francesco Miccichè; Riccardo Ricci; Alessio Giuseppe Morganti; Maria Antonietta Gambacorta; Francesca Maurizi; Claudio Coco Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-01 Impact factor: 7.038
Authors: H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Renu R Bahadoer; Esmée A Dijkstra; Boudewijn van Etten; Corrie A M Marijnen; Hein Putter; Elma Meershoek-Klein Kranenbarg; Annet G H Roodvoets; Iris D Nagtegaal; Regina G H Beets-Tan; Lennart K Blomqvist; Tone Fokstuen; Albert J Ten Tije; Jaume Capdevila; Mathijs P Hendriks; Ibrahim Edhemovic; Andrés Cervantes; Per J Nilsson; Bengt Glimelius; Cornelis J H van de Velde; Geke A P Hospers Journal: Lancet Oncol Date: 2020-12-07 Impact factor: 41.316
Authors: Fahima Dossa; Sergio A Acuna; Aaron S Rickles; Mariana Berho; Steven D Wexner; Fayez A Quereshy; Nancy N Baxter; Sami A Chadi Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Yara Backes; Sjoerd G Elias; Bibie S Bhoelan; John N Groen; Jeroen van Bergeijk; Tom C J Seerden; Hendrikus J M Pullens; Bernhard W M Spanier; Joost M J Geesing; Koen Kessels; Marjon Kerkhof; Peter D Siersema; Wouter H de Vos Tot Nederveen Cappel; Niels van Lelyveld; Frank H J Wolfhagen; Frank Ter Borg; G Johan A Offerhaus; Miangela M Lacle; Leon M G Moons Journal: BMC Med Date: 2017-07-14 Impact factor: 8.775
Authors: Ondrej Majek; Adam Gondos; Lina Jansen; Katharina Emrich; Bernd Holleczek; Alexander Katalinic; Alice Nennecke; Andrea Eberle; Hermann Brenner Journal: PLoS One Date: 2013-07-05 Impact factor: 3.240